Chronic Inflammatory Demyelinating Polyneuropathy

In a recent analysis, patients with chronic inflammatory demyelinating polyneuropathy who started their initial treatment later experienced a worsening of the disease course.

Findings suggest that autoimmune diseases including neuromyelitis optica spectrum disorder and myasthenia gravis may also benefit from BCMA-CD19 bispecific CAR-T therapy.

MoMeNtum will evaluate the efficacy and safety of DNTH103, administered subcutaneously every two weeks over a 17-week period, followed by a 52-week open-label extension to collect additional safety and efficacy data.

Across all studies, including 2 of the largest recorded for CIDP, patients unanimously demonstrated a preference for SCIG over IVIG.

Patients with CIDP treated with riliprubart reported improved quality-of-life and fatigue measures, as well as reduced neurofilament light levels.

Neurology News Network. for the week ending June 29, 2024. [WATCH TIME: 3 minutes]

A phase 3 trial showed that over time, Hyqvia is a safe and well-tolerated maintenance treatment for patients with chronic inflammatory demyelinating polyneuropathy.

Crystal, a patient living with chronic inflammatory demyelinating polyneuropathy and one of the faces of the Shining Through CIDP awareness campaign, discussed the diagnostic challenges associated with the rare disease.

In honor of Chronic Demyelinating Polyneuropathy Awareness Month, held May 2024, get caught up on some of the latest news in CIDP, with data updates and expert insights all in one place from the NeurologyLive® team.

Results show that chronic inflammatory demyelinating polyradiculoneuropathy was associated with neuromyelitis optica spectrum disorder and may be treated through a combination approach, although the mechanisms of it are still not understood.

The associate director, Patient Reported Outcomes, Johnson & Johnson, provided clarity on a poster presentation from AAN 2024 examining the most critical aspects to CIDP disease severity.

A recent study showed that the 2021 European guidelines for chronic inflammatory demyelinating polyradiculoneuropathy provided a clearer definition of variants for the disease.

A recent observational study detected anti-DLAT antibodies in the serum of patients with chronic inflammatory demyelinating polyneuropathy with a sensory-dominant phenotype.

A recent review of studies indicated that intravenous immunoglobulin could be as effective as other treatments in improving disability for patients with chronic inflammatory demyelinating polyradiculoneuropathy.

IVIg and SCIg exhibit differing effects on cytokine profiles in CIDP, potentially due to their distinct pharmacokinetics.

Takeda's FDA-approved Gammagard Liquid can be used as induction therapy, which includes an induction dose followed by maintenance doses, for adults with chronic inflammatory demyelinating polyneuropathy.

In total, 82% of patients were interested in more convenient treatments, emphasizing the importance of shared decision-making and open discussions with physicians in rare disease management.

The professor of neurology at Cedars-Sinai Medical Center shared his thoughts on potential therapies that expand management care options for patients with neuromuscular disease, in particularly for chronic inflammatory demyelinating polyneuropathy. [WATCH TIME: 4 minutes]

The professor of neurology at Cedars-Sinai Medical Center shared his clinical perspective on the recent FDA approval of Takeda’s immune globulin infusion, Hyqvia, for chronic inflammatory demyelinating polyneuropathy. [WATCH TIME: 5 minutes]

Takeda's Hyqvia is the only FDA-approved combination of immunoglobulin and hyaluronidase, which makes it a facilitated subcutaneous immunoglobulin infusion, for patients with chronic inflammatory demyelinating polyneuropathy.

Expert neurologist Richard Lewis, MD, shares his personal clinical pearls on diagnosing CIDP.

Dr Lewis describes the various investigational therapies that are underway with the potential to change the current treatment landscape of CIDP.

Expert neurologist Dr Lewis discusses the effect CIDP can have on the quality of life of a patient with CIDP as well as the unmet needs of the disease.

Dr Lewis gives an overview of the current treatment landscape of CIPD, including response rates to available treatments.

Expert neurologist Dr Lewis reviews the red flag symptoms of CIPD that should prompt a referral your patient.